Perspective Therapeutics Holds Annual Stockholders Meeting

Perspective Therapeutics ( (CATX) ) just unveiled an update.

On May 28, 2025, Perspective Therapeutics, Inc. held its Annual Meeting of Stockholders, where 82.17% of the shares were represented. During the meeting, stockholders elected Lori A. Woods, Heidi Henson, Frank Morich, Johan Spoor, and Robert Williamson to the Board until 2026, ratified WithumSmith+Brown, PC as the independent auditor for 2025, and approved executive compensation on a non-binding basis.

The most recent analyst rating on (CATX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.

Spark’s Take on CATX Stock

According to Spark, TipRanks’ AI Analyst, CATX is a Neutral.

Perspective Therapeutics is facing severe operational challenges with no revenue and increasing net losses, which significantly impact its financial performance score. While the company’s balance sheet shows some strength due to low leverage, the reliance on external financing raises sustainability concerns. The technical analysis indicates ongoing downward pressure, and the negative P/E ratio reflects severe valuation concerns. Overall, the stock’s prospects are weak, requiring strategic turnaround efforts to improve its outlook.

To see Spark’s full report on CATX stock, click here.

More about Perspective Therapeutics

Perspective Therapeutics, Inc. operates in the healthcare industry, focusing on developing innovative therapeutic solutions. The company primarily offers products and services aimed at improving patient outcomes and advancing medical treatments.

Average Trading Volume: 751,857

Technical Sentiment Signal: Sell

Current Market Cap: $178.1M

For detailed information about CATX stock, go to TipRanks’ Stock Analysis page.